VEGFA and hepatocellular carcinoma: Treatment of hypoxic Hepa1-6 mouse HCC cells with 32-134D or 33-063 revealed significant dose-dependent inhibition of hypoxia-induced ANGPTL4, EPO, PGF, and VEGFA mRNA expression with no effect on RPL13A (P < 0.05; Figure 3A and Supplemental Figure 7).